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A large proportion of vaginal and vulvar squamous cell carcinomas (SCCs) and intraepithelial neoplasias (VAIN and VIN) are
associated with HPV infection, mainly type 16. The purpose of this study was to identify HPV genotypes, as well as E6/E7 mRNA
expression of high-risk HPVs (16, 18, 31, 33, and 45) in 56 histology samples of VAIN, VIN, vaginal, and vulvar SCCs. HPV
was identiﬁed in 56% of VAIN and 50% of vaginal SCCs, 71.4% of VIN and 50% of vulvar SCCs. E6/E7 mRNA expression was
found in one-third of VAIN and in all vaginal SCCs, 42.9% of VIN and 83.3% of vulvar SCCs. Our data indicated that HPV 16
was the commonest genotype identiﬁed in VAIN and VIN and the only genotype found in SCCs of the vagina and vulva. These




tract, is particularly frequent worldwide and its majority is
transient, while at the same time, the persistent infections
caused by the oncogenic types of HPV are responsible for
cancer development. This oncogenic action of HPV is a
result of the transformation ability of the high-risk (hr) HPV
types’ oncoproteins E6 and E7. The oncogenic properties
of high-risk HPV reside in the E6 and E7 genes, which if
inappropriately expressed in dividing cells deregulate cell
division and diﬀerentiation [1].
The causal relation of HPV infection with development
of cervical cancer has been ﬁrmly established. The same
does not necessarily apply to vulvar and vaginal squamous
cell carcinomas (SCCs), where HPV is responsible for only
a smaller percentage, namely, 60–70% of vaginal SCCs [2,
3] and 38–75% of vulvar SCCs [2, 4]. Interestingly, HPV
infection is strongly associated with intraepithelial neoplasia
of the vagina (VAIN) and vulva (VIN) (93.6% and 84%,
resp.) [5]. HPV 16 is by far the commonest HPV type
identiﬁed in vaginal and vulvar SCCs and precancerous
lesions [6] .T h ea b o v ed a t am a yv a r yf r o mp o p u l a t i o nt o
population, and to our knowledge, no such analysis has been
conducted in Greece.2 Journal of Oncology
The purpose of the current study was the HPV geno-
typing, as well as the expression of E6/E7 mRNA from the
hrHPV types (16, 18, 31, 33, and 45) in Greek women with
VAIN, VIN, and SCCs of the vagina and vulva.
2.MaterialsandMethods
2.1. Study Population and Collection of Specimens. The
sam-ple of this study consisted of 56 paraﬃn-embedded
tissue sections of VAIN, VIN, or vaginal and vulvar SCCs
obtained from the Pathology Laboratory of the Regional
Anticancer Oncology Hospital of Athens “St. Savvas”. The
t i s s u e sw e r ed e p a r a ﬃnized, and total nucleic acid was
extracted using automated extraction (NucliSENS easy-
MAG, bioM´ erieux Hellas S.A). Then, genotyping of 24
HPV types was performed with microarray-based assay
(PapilloCheck HPV-Screening, Greiner Bio-One GmbH,
Germany, cat no. 465 060) as well as the expression of HPV
16, 18, 31, 33, and 45 E6/E7 mRNA, using the commercial
real-time NucliSENS EasyQ assay (NucliSENS EasyQ HPV
1.1, bioM´ erieux Hellas S.A, cat no. 290003).
Although VIN terminology was changed by the Inter-
national Society for the Study on Vulvovaginal Disease in
2004, we maintained the original terminology which was
used during the histological diagnosis [6].
Ethical approval was granted by the ethics committee
of the Regional Anticancer Oncology Hospital of Athens
“St. Savvas”, and all participants provided written informed
consent.
2.2. Deparaﬃnization. Fifteen micrometer sections of
paraﬃn-embeddedtissuesweredeparaﬃnizedbyincubation
with 100% xylene (Applichem GmbH, Darmstadt, Germany,
cat no. 10-20/21-38) at 50◦C and washings twice with
100% ethanol (Applichem GmbH, Darmstadt, Germany,
cat no. 64-17-5). Then, the pellets were dried at room
temperature for 45 minutes. Finally, deparaﬃnized samples
were digested with 100µL digestion buﬀer [1mL TE buﬀer
1X (Invitrogen corp., Calif, USA, cat no. 12090-015) and
5µL 50% Tween20 solution (Invitrogen corp., Calif, USA,
cat no. 00–3005)] and 5µL proteinase K solution (Invitrogen
corp., Calif, USA, cat no. 25530-049) at 65◦C overnight.
P r o t e i n a s eKw a sd e a c t i v a t e di nh e a tb l o c ka t8 0 ◦Cf o r1 5
minutes.
2.3. Extraction of Nucleic Acids. Tissue samples were trans-
ferred in lysis buﬀer (NucliSENS lysis buﬀer, bioM´ erieux
Hellas S.A, cat no. 200292) for 30 minutes, then total
nucleic acid was extracted by the oﬀ-board protocol with
the NucliSENS easyMAG platform (bioM´ erieux Hellas S.A),
according to the manufacturer’s instructions. The nucleic
acids were eluted in 55µLo fe l u t i o nb u ﬀer. DNA quality test
was carried out using Human Globin, Beta, Primer set kit
(MaximBiotech,Inc.,SouthSanFrancisco,CA)accordingto
manufacturer’s instructions. To assess RNA integrity, 5µgo f
RNA per sample was separated on 1% formaldehyde-agarose
gel.
2.4. HPV Genotyping (PapilloCheck HPV DNA Microarray).
The PapilloCheck HPV-Screening was used. This technology
is based on a DNA chip for the type-speciﬁc identiﬁ-
cation of 24 types of HPV (18 high-risk and 6 low-
risk types). E1-based PCR was performed according to
the manufacturer’s guidelines. For each sample, we mixed
19,8µL PapilloCheck MasterMix, 0,2µLH o t S t a r T a qp l u s
D N Ap o l y m e r a s e( 5U / µL, Qiagen, cat no. 203605), and 5µL
DNA from the tissue sample. Hybridization is followed by
mixing 30µL of the PapilloCheck hybridization buﬀer in a
fresh reaction tube with 5µL of the PCR product at room
temperature and transferring 25µL of the hybridization
mix into each compartment of the chip. We incubated
the chip for 15 minutes at room temperature in a humid
atmosphere. The chip was washed in 3 washing solutions,
centrifuged for 3 minutes at 5000rpm, and scanned on the
CheckScannerTM.
2.5. HPV E6/E7 mRNA Expression (NucliSENS EasyQ HPV
Assay). A commercial real-time NucliSENS EasyQ assay
(NucliSENS EasyQ HPV 1.1, bioM´ erieux Hellas S.A, cat no.
290003) was performed for the qualitative detection of HPV
E6/E7 mRNA of ﬁve hrHPV types (16, 18, 31, 33, and 45)
according to the manufacturer’s instructions. Firstly, three
premixes were made by adding reagent sphere diluent (Tris-
HCl, 45% DMSO) into reagent spheres (nucleotides, dith-
iotreitol, and MgCl2). In each premix, we added U1A/HPV
16, HPV 33/45, or HPV 18/31 primer and molecular beacon
mixes, KCl stock solution, and NASBA water. Secondly,
10µL of this premix was distributed to each well in a
reaction plate, and the addition of 5µLR N Af o l l o w e d .T h e
plates were incubated for 4 minutes at 65◦C to destabilize
secondary structures of RNA, followed by cooling down
to 41◦C. The reaction was started by addition of enzymes
(AMV-RT, RNase H, T7 RNA polymerase, and bovine serum
albumin) and measured in real time using the Lambda FL
600 ﬂuorescence reader (Bio-Tek, Winooski, VT) at 41◦Cf o r
2h o u r sa n d3 0m i n u t e s .
2.6. Statistical Analysis. Our data were analyzed using SAS
v9.0. Absolute and relative frequencies were used to present
the HPV prevalence according to age and histology. Chi-
squared tests were performed to assess the statistical signif-
icance of any diﬀerences in prevalence. t-test was used, along
with relevant descriptive statistics (mean value, standard
deviation, and 95% conﬁdence interval for the mean value)
tocomparetheaverageageamongpatientsdependingonthe
prevalence of HPV and histology. In all the statistical tests,




3.1. Vaginal Intraepithelial Neoplasia and Vaginal Squamous
Cell Carcinoma. This group consisted of 18 patients with
VAIN (mean age 46.2 years) and 4 patients with SCCs (mean























Figure 1: Prevalence of the hr HPV genotypes (16, 18, 31, 33, and
45)detectedbybothPapilloCheckDNAMicroarrayandNucliSENS
EasyQ HPV assay according to histological status of samples of
vagina.
and 10 as VAIN II/III. HPV infection was detected in 56% of
VAIN (10/18) and in 50% of vaginal SCCs (2/4). Detectable
HPVDNAfromatleastoneofthe24genotypeswasfoundin
75% (6/8) of cases of VAIN I and 40% (4/10) of VAIN II/III.
In VAIN cases, the presence of HPV infection was strongly
associated with younger patient age (38.7 versus 55.6 years,
P = 0.006).
hrHPV types were found in 70% (7/10) and lrHPV types
in 30% (3/10) of VAIN cases. Only hrHPVs were detected in
vaginal SCCs (2/2). Multiple HPV types were present only in
one case (one VAIN II/III sample contained HPV 33 and 53).
The commonest HPV genotype was HPV 42 for VAIN
I samples (3/6 cases, 50%), followed by HPV 16 (2/6 cases,
33.3%) and HPV 39 (1/6 cases, 16.7%), while HPV16 and
HPV33 were the most common types for VAIN II/III (2/4
cases, 50% each). HPV 16 was the only type associated with
HPV-infected vaginal SCCs (2/2 cases, 100%).
Regarding the hrHPV types 16, 18, 31, 33, and 45, 33.3%
(6/18) ofthe VAINand 50%of vaginal SCCs wereHPVDNA
positive for at least one of the above types. The detection
r a t e so ft h eﬁ v eh r H P Vt y p e si ns a m p l e sf r o mw o m e nw i t h
diﬀerent grades of VAIN and SCCs are provided in Figure 1.
All vaginal SCCs (4/4) and 60% (6/10) of VAIN II/III
were positive for HPV E6/E7 mRNA expression. This was
statistically signiﬁcantly higher than VAIN I samples, where
noHPVE6/E7mRNAexpressionwasdetected(P = 0.01and
P = 0.002), respectively (Figure 1).
The expression pattern for hrHPV types 16, 18, 31, 33,
and 45, according to VAIN grade and SCCs, is summarized
in Table 1.
The concordance between the HPV DNA test (Papillo-
Check DNA Microarray) and HPV E6/E7 mRNA test (Nucli-
SENS EasyQ HPV assay) results was poor for patients with
VAIN I (75%; kappa = 0.00) and vaginal SCCs (50%; kappa
Table 1: Distribution of diﬀerent HPV types detected by Nucli-
SENS EasyQ HPV assay.
Histology result HPV types
HPV16 HPV18 HPV31 HPV33 HPV45
VAIN I




VIN II/III 6 2
Vulvar SCCs 3 2
Total (n.17) 13 2 2
Distribution of the ﬁve high-risk HPV types determined by NucliSENS
EasyQ HPV assay in the vaginal and vulvar tissue samples.
= 0.00), whereas it was good for patients with VAIN II/III
(80%; kappa = 0.62) (Table 2).
3.2. Vulvar Intraepithelial Neoplasia and Vulvar Squamous
Cell Carcinoma. We included 28 patients with VIN, half of
which had a low-grade lesion (mean age 35 years) and 6
patients with vulvar SCCs (mean age 62.5 years). VIN cases
were not associated with lichen sclerosus, diﬀerentiated vul-
var intraepithelial neoplasia, or squamous cell hyperplasia.
PapilloCheck DNA Microarray detected HPV infection in
71.4% of VIN samples (20/28) and in 50% of vulvar SCCs
(3/6). HPV DNA from at least one of the 24 genotypes was
detectedin64.3%(9/14) ofwomenwithVINI,and78.6%of
those with VIN II/III (11/14). In VIN cases, the presence of
HPV infection was associated with younger patient age (31.7
versus 43.1 years, P = 0.001).
PapilloCheck assay detected hrHPV infection in all VIN
cases and vulvar SCCs. Multiple infection was detected in 5
cases (3 VIN I cases contained HPV 6/16, HPV 6/16/59 and
11/59, resp., and 2 VIN II/III cases contained HPV 16/53 and
HPV 16/51/66, resp.).
HPV16 and HPV59 were the most commonly observed
for infected VIN I samples (4/9 cases each and one case
with multiple infection HPV 6/16/59, 55.6% each), while
HPV16 was the commonest genotype for VIN II/III (9/11
cases, 81.8%) followed by types 18, 51, 52, 53, and 66 (1/11
cases, 9.1% each). In HPV-positive vulvar SCCs, only HPV
16 was present (3/3 cases, 100%).
Regarding the hrHPV types 16, 18, 31, 33, and 45,
53.6% (15/18) of VIN and 50% of vulvar SCCs were HPV
DNA positive for at least one of the above HPV types by
PapilloCheckDNAMicroarray.Thedetectionratesoftheﬁve
hrHPV types in samples from women with diﬀerent grades
of VIN and SCCs are provided in Figure 2.
42.9% of VIN samples (12/28) and 83.3% of vulvar SCCs
(5/6) were positive for HPV E6/E7 mRNA expression. There
was a higher prevalence of E6 and E7 mRNA expression in
patients with higher-grade lesions as shown in Figure 2.T h e
diﬀerence in detection of E6/E7 mRNA expression between
VIN I and vulvar SCCs was statistically signiﬁcant (P =
0.04).4 Journal of Oncology
Table 2: Concordance between HPV DNA test (PapilloCheck DNA Microarray) and HPV E6/E7 mRNA test (NucliSENS EasyQ HPV assay)
by histological status of samples.
No. of specimens Number of specimens positive with Concordance∗ % Kappa value P
HPV DNA test E6/E7 mRNA test
VAIN I 8 2 0 6/8 75.0 0.00 1.00
VAIN II/III 10 4 6 8/10 80.0 0.62 0.08
Vaginal SCCs 4 2 4 2/4 50.0 0.00 1.00
VIN I 14 5 4 13/14 92.9 0.84 0.005
VIN II/III 14 10 8 8/14 57.1 0.09 1.00
Vulvar SCCs 6 3 5 4/6 66.7 0.33 1.00
∗Thedatarepresentthenumberof samplesfor which theresultsfromPapilloCheckDNAMicroarrayandNucliSENSEasyQHPVassay were concordant/total
























Figure 2: Prevalence of hr HPV genotypes (16, 18, 31, 33 and 45)
detected by both PapilloCheck DNA Microarray and NucliSENS
EasyQ HPV assay according to histological status of samples of
vulva.
HPV16 was the commonest type revealed by NucliSENS
EasyQ HPV assay for VIN I, VIN II/III, and vulvar SCCs
(4/4 cases: 100%, 6/8 cases: 75%, and 3/5 cases: 60%, resp.)
(Table 1).
The concordance between the HPV DNA test (Papillo-
Check DNA Microarray) and HPV E6/E7 mRNA test (Nucli-
SENS EasyQ HPV assay) results was very good for samples
classiﬁedashavingVINI(92.9%;kappa=0.84)butwaspoor
forpatientswithVINII/III(57.1%;kappa=0.09).Inthecase
of samples classiﬁed as having vulvar SCCs, the concordance
was fair (66.7%; kappa = 0.33) (Table 2).
4. Discussion
The goal of this study was to investigate HPV typing and
HPV E6/E7 mRNA expression with intraepithelial neoplasia
and squamous cell carcinomas of the vagina and vulva. This
is the ﬁrst study to report the association between HPV
infectionwithoncogenicexpressionandvulvovaginaldisease
in Greek women.
The role of HPV infection in vulvar intraepithelial
neoplasia and squamous cell carcinoma has been conﬁrmed
through multiple studies worldwide. Although a similar link
exists in vaginal precancerous and cancerous lesions, this has
not been ﬁrmly established. This in part is due to the fact
that VAIN and vaginal carcinomas are less common than
their vulvar and cervical counterparts, due to the absence
of a susceptible transformation zone and the protective
eﬀect of the keratinized vaginal mucosa [7]. Furthermore,
it is possible that a proportion of VAIN lesions remain
undiagnosed as they are asymptomatic and not easy to
visualize during a routine gynecological examination [5].
Nevertheless, we expect an outbreak of VAIN and VIN cases,
as well as SCCs of the vulva and vagina, especially in younger
women[8, 9]. This is thought to be due to not only the
rapid spread of HPV, but also the increased gynecological
surveillance and improved diagnostic techniques, aimed at
the identiﬁcation of cervical lesions.
As mentioned above, several studies have previously de-
scribed the HPV prevalence and genotype distribution in
VIN and SCCs of the vulva [3, 4, 10–16]. The results of the
current study are generally similar to worldwide VIN and
vulvar SCCs data although some diﬀerences were observed.
In our study, the overall HPV prevalence was 71.4% in VIN
and 50% in vulvar carcinoma. A recent international meta-
analysis of 14 studies on vaginal and 63 studies on vulvar
lesions reported that the overall HPV prevalence in VIN was
84.0% and 40.4% in vulvar SCCs [5]. Similar results were
reported by other studies which indicated HPV prevalence of
79.6% in VIN and 40.1% in vulvar SCCs [15, 16]( Table 4).
According to our results, hrHPV infection was the most
frequently observed in VIN I cases. This is contrary to data
obtained from an older study [3], where low-risk (lr) HPVs
were the commonest types. HPV 16 and HPV 59 were the
twomostfrequentgenotypesinVINI,accountingfor35.7%,
whereas in the recent international meta-analysis HPV 6 was
found to be the commonest genotype [5]. HPV 16 was by far
the commonest type in VIN II/III and vulvar SCCs in our
study, accounting for 64.3%, similar to other reports [4, 14]
(Table 4).Journal of Oncology 5








(review) 66 PCR/hybrid capture assays
Any HPV, 98.5%





107 PGMY reverse line blot/SPF 10 line probe
assay, blot hybridization
Any HPV, 100%
Most common types; 16 (23.4%),
56 (11.0%), 51 (8.8%)
VAIN II/III
Smith 166 PCR/hybrid capture assays Any HPV, 92.6%
Most common type; 16 (65.8%)
De Vuyst 191
PGMY reverse line blot/SPF 10 line probe
assay, blot/southern hybridization,
restriction fragment analysis, sequencing
Any HPV, 90.1%
Most common types; 16 (57.6%),
18 (6.9%), 58 (5.9%)
Vaginal SCC
Smith 83 PCR/hybrid capture assays Any HPV, 65.5%
Most common type; 16 (55.4%)
De Vuyst 136
Reverse line blot assay, INNO-LiPA HPV
genotyping, southern hybridization,
restriction fragment analysis, sequencing
Any HPV, 69.9%
Most common types; 16 (53.7%),
18 (7.6%), 31 (5.6%)
35.7% of VIN I samples harbored hrHPV (16, 18, 31, 33,
and 45) and this rose to 71.4% in VIN II/III samples. This is
expected as women with hrHPV infection are more likely to
progress to high-grade lesions. Interestingly, the percentage
of hrHPV dropped to 50% in vulvar SSCs. This suggests that
the virus was present only at very low copy numbers and/or
that only a speciﬁc region of viral DNA was integrated into
the host’s genome [17].
In our study, HPV prevalence in VAIN samples was 56%.
This was signiﬁcantly lower than those reported by De Vuyst
etal.(93,6%)andSmithetal.(95.6%).InvaginalSCCs,HPV
prevalence was 50%. This was lower but more comparable
to those found in the studies mentioned above (65.5% and
69.9%, resp.) [5, 15]( Table 3).
In a worldwide meta-analysis, the most frequent geno-
types were HPV 16, 56, and 51 in patients with VAIN I
lesions, HPV 16, 18, and 58 in those with VAIN II/III, and
HPV 16, 18, and 31 in those with vaginal SCCs [5]( Table 3).
In our study, we detected, in decreasing order, HPV 42, 16,
and 39 in VAIN I cases, HPV 16, 33, and 53 in VAIN II/III,
cases, and HPV 16 in SCCs. It is interesting to note that HPV
18 was not identiﬁed in any of our VAIN or SCC samples,
as opposed to what is seen elsewhere, and this may be a
geographical variation that needs to be investigated further.
Anothervariation,possiblyattributedtoourdiﬀerentsample
population, was that HPV 42, a lrHPV type, was the most
frequently identiﬁed type in VAIN I, whereas in the studies
by De Vuyst et al. and Smith et al., no lrHPVs were detected
in low-grade lesions [5, 15].
Contrary to what was observed in vulvar samples, the
proportion of patients with detectable hrHPV (16, 18, 31,
33,and45)increasedprogressivelyasthegradeofthevaginal
lesion progressed.
Using the NucliSens EasyQ HPV assay, we investigated
HPV oncoprotein expression in diﬀerent grades of dysplasia
and carcinoma. The results from E6/E7 mRNA test related
well with the grade of lesion. The lowest rates of hrHPV
types (16, 18, 31, 33, and 45) E6/E7 mRNA expression
were for patients with low-grade vulvar lesions (VIN I),
whereas the higher rates were seen in high-grade lesions
(VIN II/III), which is in accordance with what is seen in
cervical lesions [18–20]. It is possible that VIN I lesions that
have detectable E6/E7 mRNA expression are the ones with a
potentialtoprogresstohigher-gradelesionsandmalignancy,
and therefore, E6/E7 mRNA expression could be used as a
screening marker for better surveillance in this subcategory
of women. Interestingly, none of the ﬁve high-risk types
E6/E7 mRNA expression was detected in low-grade vaginal
lesions (VAIN I). The above ﬁndings probably suggest that
VAIN I may not be strictly a precancerous disease, while
at the same time, they reﬂect the transient nature of most
HPVinfections.Onthecontrary,VINII/III,VAINII/III,and
vaginal and vulvar SCCs showed a high prevalence of E6/E7
mRNA expression. For VIN II/III in particular, the rates of
E6/E7 mRNA expression that we found were signiﬁcantly
higher than what has been published previously (57.1 versus
38.1%) [21].
In our series, there was a signiﬁcantly higher detection of
HPV 16 by NucliSens EasyQ HPV assay when compared to
other hrHPV types for both vaginal and vulvar cases. This
indicates that HPV 16 may be related to a diﬀerent nature of
persistentinfectionandoncoproteinexpressioninthevagina
and vulva in comparison to HPV types 18, 31, 33, and 45.
On the basis of DNA and mRNA assays, DNA from HPV
was detected more frequently in vulvar low-grade lesions
than E6/E7 mRNA expression. This data possibly reﬂects6 Journal of Oncology








(review) 71 PCR/hybrid capture assays
Any HPV, 77.5%





90 PGMY reverse line blot/SPF 10 line probe
assay
Any HPV, 67.8%





31 Reverse line blot assay Any HPV, 80.6%
Most common types; 6 or 11 (64.5%)
VIN II/III
Smith 1340 PCR/hybrid capture assays
Any HPV, 80.4%
Most common types; 16 (71.2%), 33
(7.7%)
De Vuyst 1061
PGMY reverse line blot/SPF 10 line probe




Most common types; 16 (71.9%), 33
(8.0%),18 (5.0%)
Garland 31 Reverse line blot assay
Any HPV, 87.1%
Most common types; 16 (64.5%), 6, or
HPV11 (29%)
Vulvar SCC
Smith 1379 PCR/hybrid capture assays
Any HPV, 40.1%
Most common types; 16 (29.3%), 18
(5.6%)
De Vuyst 1873 Reverse line blot hybridization, dot blot
hybridization, Roche HPV linear array
Any HPV, 40.4%
Most common HPV types; 16 (32.2%),
33 (4.5%), 18 (4.4%)
an episomal state or low number of copies of the virus.
However, E6/E7 mRNA expression in a number of VIN
I indicates that hrHPV may be oncogenically active even
before it produces detectable changes in the cell [17].
For vaginal high-grade lesions and carcinomas, as well as
vulvar carcinomas, a higher rate of E6/E7 mRNA expression
was observed, compared to HPV DNA. This suggests that
the presence of E6/E7 oncoproteins is a speciﬁc marker for
high-grade lesions. Interestingly, 2 cases of VAIN II/III, 1
case of VIN II/III, 2 cases of vaginal SCCs, and 2 cases of
vulvar SCCs were positive only for mRNA expression. This
may be explained by the fact that total viral DNA has been
integrated to the host genome, and therefore, it cannot be
detected by the DNA test. It is important to notice that in
vulvar high-grade lesions a higher detection rate for HPV
DNA was observed compared to E6/E7 mRNA expression.
It is possible that these results were due to a very low level of
viral transcriptional activity.
The sample in our study was relatively small, primarily
due to the low incidence of vulvar and vaginal intraepithelial
neoplasias and carcinomas. Thus, we can only provide a
rough estimate of the relative importance of each HPV type
with regards to vaginal and vulvar cancer and precancer in
our population.
Another limitation of our study was that histology types
of vulvar SCCs were not available, so a correlation between
histology types and HPV infection was not possible. Never-
theless, it has been suggested that diﬀerentiated keratinizing
SCCS, which occurs more frequently in elderly women, is
not associated with HPV infection, whereas nonkeratinizing
SCCS, which primarily aﬀects younger women, is caused
by hrHPV infection [22]. This was indirectly conﬁrmed in
our study, as HPV infection was more likely to be found in
younger women.
5. Conclusion
This study described the detection rates and attribution of
genital HPV types, as well as the E6/E7 mRNA expression
of intraepithelial neoplasias and squamous cell carcinomas
of the vagina and vulva in Greek women. In summary, our
results showed that a very crucial percentage of HPV was
associated with VIN, VAIN, and vaginal/vulvar SCCs, and
HPV 16 accounted for most HPV-positive cases. The fact
that some cases of vulvar low grade lesions were positive for
E6/E7 mRNA expression is also of interest, as it may identify
theselesionsasmoreclearlyprecancerous.Astrikingincrease
especially in the incidence of VIN in young women has beenJournal of Oncology 7
reportedinthelastdecadesinsomehigh-resourcescountries
[8, 23, 24].
Further research is required to better assess the role of
mRNA testing as a molecular marker for vaginal and vulvar
carcinogenesis.
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